ZURA BIO LTD ZURA
CLASS A ORD SHS · Common Stock · CUSIP G9TY5A101
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- HeadquartersLa Jolla, CA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once ($8.9k this quarter). Holder counts are more reliable. Shares outstanding: 43.1m as of 2023-08-14, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $8.18.
Trends to Q2 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2023 | 3 |
| Q2 2023 | 39 |
Biggest buyers
| GREAT POINT PARTNERS LLC | New | +3.3m |
| MONTANOVA CAPITAL, LLC | New | +2.9m |
| Deep Track Capital, LP | New | +2.5m |
| ARMISTICE CAPITAL, LLC | New | +950.0k |
| CITADEL ADVISORS LLC | New | +712.9k |
| Point72 Asset Management, L.P. | New | +469.3k |
| BlackRock Inc. | New | +406.1k |
| Monashee Investment Management LLC | New | +240.0k |
| VANGUARD GROUP INC | New | +228.4k |
| GEODE CAPITAL MANAGEMENT, LLC | New | +200.6k |
Biggest sellers
| SONA ASSET MANAGEMENT (US) LLC | Sold out | -24.5k |
| UBS Group AG | Sold out | -1.2k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| AI Biotechnology LLC 13D · may seek influence -1.7 pts · filed 2026-03-02 | 18.2% |
Athanor Capital
13D · may seek influence
no change · filed 2026-01-27
Stated purposeThe securities reported herein were acquired by the Reporting Persons for investment purposes in the ordinary course of business. The Reporting Persons acquired the securities without the purpose or effect of changing or influencing the control of the Issuer and do not have any present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through 4(j) of Schedule 13D. The Reporting Persons may, from time to time, review their investment in the Issuer and may engage in discussions with management or the board of directors of the Issuer regarding the Issuer's business, operations and prospects, subject to applicable law. The Reporting Persons reserve the right to determine in the future whether to change the purpose or purposes described above or wh… Full filing |
15.7% |
| Venrock Healthcare Capital Partners III, L.P. 13G · passive investor no change · filed 2026-05-15 | 9.9% |
| SUVRETTA CAPITAL MANAGEMENT, LLC 13G · passive investor +1.3 pts · filed 2026-05-12 | 9.9% |
Fell to 5% or below in the last year: GREAT POINT PARTNERS LLC (4.4%, 2026-05-15), JPMORGAN CHASE & CO (4.7%, 2026-05-06)
Insider purchases and sales in Q2 2023
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 0 | — | 0 | — | — |
| Q1 2022 | 0 | — | 0 | — | — |
| Q2 2022 | 0 | — | 0 | — | — |
| Q3 2022 | 0 | — | 0 | — | — |
| Q4 2022 | 0 | — | 0 | — | — |
| Q1 2023 | 0 | — | 0 | — | — |
| Q2 2023 | 1 | $500.0k | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2023-06-05 | Munshi Amit Director | Bought | $500.0k117.6k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q2 2023
| Manager | Shares | Change |
|---|---|---|
| GREAT POINT PARTNERS LLC 5.41% of their portfolio | 3.3m $27.0m | New |
| MONTANOVA CAPITAL, LLC 1.25% of their portfolio | 2.9m $23.4m | New |
| Deep Track Capital, LP 0.97% of their portfolio | 2.5m $20.7m | New |
| ARMISTICE CAPITAL, LLC 0.20% of their portfolio | 950.0k $7.8m | New |
| CITADEL ADVISORS LLC 0.01% of their portfolio | 712.9k $5.6m | New |
| Point72 Asset Management, L.P. 0.01% of their portfolio | 469.3k $3.8m | New |
| BlackRock Inc. 0.00% of their portfolio | 406.1k $3.3m | New |
| Monashee Investment Management LLC 0.47% of their portfolio | 240.0k $2.0m | New |
| VANGUARD GROUP INC 0.00% of their portfolio | 228.4k $1.9m | New |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 200.6k $1.6m | New |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 0.03% of their portfolio | 167.2k $1.4m | Not comparable |
| STATE STREET CORP 0.00% of their portfolio | 165.9k $1.4m | New |
| SILVERARC CAPITAL MANAGEMENT, LLC 0.44% of their portfolio | 160.0k $1.3m | New |
| Eisler Capital (UK) Ltd. 0.09% of their portfolio | 100.0k $820.0k | New |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.00% of their portfolio | 72.9k $598.0k | New |
| NORTHERN TRUST CORP 0.00% of their portfolio | 69.9k $572.9k | New |
| RAYMOND JAMES & ASSOCIATES 0.00% of their portfolio | 67.9k $556.6k | New |
| Invesco Ltd. 0.00% of their portfolio | 59.1k $484.7k | New |
| ALLIANCEBERNSTEIN L.P. 0.00% of their portfolio | 23.4k $191.9k | New |
| Nuveen Asset Management, LLC 0.00% of their portfolio | 17.2k $141.4k | New |
| HRT FINANCIAL LP 0.00% of their portfolio | 10.2k $83.0k | New |
| NEW YORK STATE COMMON RETIREMENT FUND 0.00% of their portfolio | 8.4k $68.9k | New |
| RHUMBLINE ADVISERS 0.00% of their portfolio | 8.1k $66.5k | New |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 8.1k $66.5k | New |
| JPMORGAN CHASE & CO 0.00% of their portfolio | 6.0k $49.6k | New |
| MORGAN STANLEY 0.00% of their portfolio | 5.4k $44.5k | New |
| AMERICAN INTERNATIONAL GROUP, INC. 0.00% of their portfolio | 3.6k $29.9k | New |
| WELLS FARGO & COMPANY/MN 0.00% of their portfolio | 2.9k $23.9k | New |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 0.00% of their portfolio | 2.5k $20.7k | New |
| CITIGROUP INC 0.00% of their portfolio | 2.3k $18.5k | New |
| STRS OHIO 0.00% of their portfolio | 1.6k $13.0k | New |
| BARCLAYS PLC 0.00% of their portfolio | 1.5k $12.4k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 1.3k $10.4k | Added +1.2k |
| Point72 Middle East FZE 0.00% of their portfolio | 1.1k $8.9k | New |
| IFP Advisors, Inc 0.00% of their portfolio | 1.0k $7.7k | New |
| AMALGAMATED BANK 0.00% of their portfolio | 738 $6.0k | New |
| Ameritas Investment Partners, Inc. 0.00% of their portfolio | 626 $5.1k | New |
| FMR LLC 0.00% of their portfolio | 283 $2.3k | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | New |